Delaware
|
20-8133057
|
(State
or other jurisdiction of
|
(I.R.S.
Employer
|
incorporation
or organization)
|
Identification
No.)
|
Large
accelerated filer ¨
|
Accelerated
filer ¨
|
Non-accelerated
filer ¨
(Do not check if a smaller reporting company)
|
Smaller
reporting company x
|
Page
Number
|
||
PART
I
|
||
Item
1. Financial Statements
|
3
|
|
Item
2. Management’s Discussion and Analysis of Financial Condition and Results
of Operations
|
28
|
|
Item
3. Quantitative and Qualitative Disclosures About Market
Risk
|
32
|
|
Item
4T. Controls and Procedures
|
32
|
|
PART
II
|
||
Item
1. Legal Proceedings
|
33
|
|
Item
1A. Risk Factors
|
33
|
|
Item
5. Other Information
|
33
|
|
Item
6. Exhibits
|
33
|
Page
|
|
Consolidated
Balance Sheets
|
4
|
Consolidated
Statements of Operations
|
5
|
Statements
of Changes in Stockholders' Equity (Deficiency)
|
6 -
10
|
Consolidated
Statements of Cash Flows
|
11
|
Notes
to Consolidated Financial Statements
|
12
- 27
|
March
31,
|
December
31,
|
|||||||
2009
|
2008
|
|||||||
Unaudited
|
Audited
|
|||||||
ASSETS
|
||||||||
CURRENT
ASSETS:
|
||||||||
Cash
and cash equivalents
|
$ | 2 | $ | 2 | ||||
Restricted
cash
|
32 | 36 | ||||||
Accounts
receivable and prepaid expenses
|
43 | 21 | ||||||
Total current
assets
|
77 | 59 | ||||||
LONG-TERM
INVESTMENTS:
|
||||||||
Prepaid
expenses
|
6 | 11 | ||||||
Severance
pay fund
|
54 | 62 | ||||||
Total long-term
investments
|
60 | 73 | ||||||
PROPERTY
AND EQUIPMENT, NET
|
704 | 743 | ||||||
Total
assets
|
$ | 841 | $ | 875 | ||||
LIABILITIES
AND STOCKHOLDERS' DEFICIENCY
|
||||||||
CURRENT
LIABILITIES:
|
||||||||
Short
term Credit from bank
|
$ | 37 | $ | 72 | ||||
Trade
payables
|
764 | 744 | ||||||
Other
accounts payable and accrued expenses
|
1,865 | 1,672 | ||||||
Short-term
convertible loans
|
175 | 172 | ||||||
Short-term
loans
|
200 | 199 | ||||||
Total current
liabilities
|
3,041 | 2,859 | ||||||
ACCRUED
SEVERANCE PAY
|
81 | 92 | ||||||
Total
liabilities
|
3,122 | 2,951 | ||||||
COMMITMENTS
AND CONTINGENCIES
|
||||||||
STOCKHOLDERS'
DEFICIENCY:
|
||||||||
Stock
capital: (Note 7)
|
||||||||
Common
stock of $0.00005 par value - Authorized: 800,000,000 shares at March 31,
2009 and December 31,2008; Issued and outstanding:
55,241,418 shares at March 31, 2009 and December 31,
2008,
|
3 | 3 | ||||||
Additional
paid-in-capital
|
34,190 | 33,881 | ||||||
Deficit
accumulated during the development stage
|
(36,474 | ) | (35,960 | ) | ||||
Total
stockholders' deficiency
|
(2,281 | ) | (2,076 | ) | ||||
Total
liabilities and stockholders' deficiency
|
$ | 841 | $ | 875 |
Three
months ended March
31,
|
Period from
September
22,
2000
(inception
date)
through
March
31,
|
|||||||||||
2009
|
2008
|
2009
|
||||||||||
Unaudited
|
Unaudited
|
|||||||||||
Operating
costs and expenses:
|
||||||||||||
Research
and development, net
|
$ | 289 | $ | 590 | $ | 21,793 | ||||||
General
and administrative
|
251 | 544 | 11,940 | |||||||||
Total operating
costs and expenses
|
540 | 1,134 | 33,733 | |||||||||
Financial
income (expenses), net
|
26 | (128 | ) | (2,524 | ) | |||||||
514 | 1,262 | 36,257 | ||||||||||
Taxes
on income
|
- | - | 53 | |||||||||
Loss
from continuing operations
|
514 | 1,262 | 35,310 | |||||||||
Net
loss from discontinued operations
|
- | - | 164 | |||||||||
Net
loss
|
$ | 514 | $ | 1,262 | $ | 36,474 | ||||||
Basic
and diluted net loss per share from continuing
operations
|
$ | 0.01 | $ | 0.03 | ||||||||
Weighted
average number of shares outstanding used in
computing basic and diluted net loss per share
|
55,241,418 | 41,774,344 |
Deficit
accumulated
|
Total
|
|||||||||||||||||||||||
Additional
|
Deferred
|
during
the
|
stockholders'
|
|||||||||||||||||||||
Common
stock
|
paid-in
|
stock-based
|
development
|
equity
|
||||||||||||||||||||
Number
|
Amount
|
capital
|
compensation
|
stage
|
(deficiency)
|
|||||||||||||||||||
Balance
as of September 22, 2000 (date of inception)
|
- | $ | - | $ | - | $ | - | $ | - | $ | - | |||||||||||||
Stock
issued on September 22, 2000 for cash at $0.00188 per
share
|
8,500,000 | 1 | 16 | - | - | 17 | ||||||||||||||||||
Stock
issued on March 31, 2001 for cash at $0.0375 per share
|
1,600,000 | * - | 60 | - | - | 60 | ||||||||||||||||||
Contribution
of capital
|
- | - | 8 | - | - | 8 | ||||||||||||||||||
Net
loss
|
- | - | - | - | (17 | ) | (17 | ) | ||||||||||||||||
Balance
as of March 31, 2001
|
10,100,000 | 1 | 84 | - | (17 | ) | 68 | |||||||||||||||||
Contribution
of capital
|
- | - | 11 | - | - | 11 | ||||||||||||||||||
Net
loss
|
- | - | - | - | (26 | ) | (26 | ) | ||||||||||||||||
|
||||||||||||||||||||||||
Balance
as of March 31, 2002
|
10,100,000 | 1 | 95 | - | (43 | ) | 53 | |||||||||||||||||
|
||||||||||||||||||||||||
Contribution
of capital
|
- | - | 15 | - | - | 15 | ||||||||||||||||||
Net
loss
|
- | - | - | - | (47 | ) | (47 | ) | ||||||||||||||||
|
||||||||||||||||||||||||
Balance
as of March 31, 2003
|
10,100,000 | 1 | 110 | - | (90 | ) | 21 | |||||||||||||||||
2-for-1
stock split
|
10,100,000 | * - | - | - | - | - | ||||||||||||||||||
Stock
issued on August 31, 2003 to purchase mineral option at $0.065 per
share
|
100,000 | * - | 6 | - | - | 6 | ||||||||||||||||||
Cancellation
of shares granted to Company's President
|
(10,062,000 | ) | * - | * - | - | - | - | |||||||||||||||||
Contribution
of capital
|
- | * - | 15 | - | - | 15 | ||||||||||||||||||
Net
loss
|
- | - | - | - | (73 | ) | (73 | ) | ||||||||||||||||
Balance
as of March 31, 2004
|
10,238,000 | $ | 1 | $ | 131 | $ | - | $ | (163 | ) | $ | (31 | ) |
Deficit
accumulated
|
Total
|
|||||||||||||||||||||||
Additional
|
Deferred
|
during
the
|
stockholders'
|
|||||||||||||||||||||
Common
stock
|
paid-in
|
stock-based
|
development
|
equity
|
||||||||||||||||||||
Number
|
Amount
|
capital
|
compensation
|
stage
|
(deficiency)
|
|||||||||||||||||||
Balance
as of March 31, 2004
|
10,238,000 | $ | 1 | $ | 131 | $ | - | $ | (163 | ) | $ | (31 | ) | |||||||||||
Stock
issued on June 24, 2004 for private placement at $0.01 per share, net of
$25,000 issuance expenses
|
8,510,000 | * - | 60 | - | - | 60 | ||||||||||||||||||
Contribution
capital
|
- | - | 7 | - | - | 7 | ||||||||||||||||||
Stock
issued in 2004 for private placement at $0.75 per unit
|
1,894,808 | * - | 1,418 | - | - | 1,418 | ||||||||||||||||||
Cancellation
of shares granted to service providers
|
(1,800,000 | ) | * - | - | - | - | ||||||||||||||||||
Deferred
stock-based compensation related to options granted to
employees
|
- | - | 5,979 | (5,979 | ) | - | - | |||||||||||||||||
Amortization
of deferred stock-based compensation related to shares and options granted
to employees
|
- | - | - | 584 | - | 584 | ||||||||||||||||||
Compensation
related to shares and options granted to service providers
|
2,025,000 | * - | 17,506 | - | - | 17,506 | ||||||||||||||||||
Net
loss
|
- | - | - | - | (18,840 | ) | (18,840 | ) | ||||||||||||||||
Balance
as of March 31, 2005
|
20,867,808 | $ | 1 | $ | 25,101 | $ | (5,395 | ) | $ | (19,003 | ) | $ | 704 |
Deficit
accumulated
|
Total
|
|||||||||||||||||||||||
Additional
|
Deferred
|
during
the
|
stockholders'
|
|||||||||||||||||||||
Common
stock
|
paid-in
|
stock-based
|
development
|
equity
|
||||||||||||||||||||
Number
|
Amount
|
capital
|
compensation
|
stage
|
(deficiency)
|
|||||||||||||||||||
Balance
as of March 31, 2005
|
20,867,808 | $ | 1 | $ | 25,101 | $ | (5,395 | ) | $ | (19,003 | ) | $ | 704 | |||||||||||
Stock
issued on May 12, 2005 for private placement at $0.8 per
share
|
186,875 | * - | 149 | - | - | 149 | ||||||||||||||||||
Stock
issued on July 27, 2005 for private placement at $0.6 per
share
|
165,000 | * - | 99 | - | - | 99 | ||||||||||||||||||
Stock
issued on September 30, 2005 for private placement at $0.8 per
share
|
312,500 | * - | 225 | - | - | 225 | ||||||||||||||||||
Stock
issued on December 7, 2005 for private placement at $0.8 per
share
|
187,500 | * - | 135 | - | - | 135 | ||||||||||||||||||
Forfeiture
of options granted to employees
|
- | - | (3,363 | ) | 3,363 | - | - | |||||||||||||||||
Deferred
stock-based compensation related to shares and options granted to
directors and employees
|
200,000 | * - | 486 | (486 | ) | - | - | |||||||||||||||||
Amortization
of deferred stock-based compensation related to options and shares granted
to employees and directors
|
- | - | 51 | 1,123 | - | 1,174 | ||||||||||||||||||
Stock-based
compensation related to options and shares granted to service
providers
|
934,904 | * - | 662 | - | - | 662 | ||||||||||||||||||
Reclassification
due to application of EITF 00-19
|
- | - | (7,906 | ) | (7,906 | ) | ||||||||||||||||||
Beneficial
conversion feature related to a convertible bridge loan
|
- | - | 164 | - | - | 164 | ||||||||||||||||||
Net
loss
|
- | - | - | - | (3,317 | ) | (3,317 | ) | ||||||||||||||||
Balance
as of March 31, 2006
|
22,854,587 | $ | 1 | $ | 15,803 | $ | (1,395 | ) | $ | (22,320 | ) | $ | (7,911 | ) | ||||||||||
Elimination
of deferred stock compensation due to implementation of SFAS
123(R)
|
- | - | (1,395 | ) | 1,395 | - | - | |||||||||||||||||
Stock-based
compensation related to shares and options granted to directors and
employees
|
200,000 | * - | 1,168 | - | - | 1,168 | ||||||||||||||||||
Reclassification
due to application of EITF 00-19
|
- | - | 7,191 | - | - | 7,191 | ||||||||||||||||||
Stock-based
compensation related to options and shares granted to service
providers
|
1,147,225 | - | 453 | - | - | 453 | ||||||||||||||||||
Warrants
issued to convertible note holder
|
- | - | 11 | - | - | 11 | ||||||||||||||||||
Warrants
issued to loan holder
|
- | - | 110 | - | - | 110 | ||||||||||||||||||
Beneficial
conversion feature related to convertible bridge loans
|
- | - | 1,086 | - | - | 1,086 | ||||||||||||||||||
Net
loss
|
- | - | - | - | (3,924 | ) | (3,924 | ) | ||||||||||||||||
Balance
as of December 31, 2006
|
24,201,812 | $ | 1 | $ | 24,427 | $ | - | $ | (26,244 | ) | $ | (1,816 | ) |
Additional
paid-in
|
Deficit
accumulated
|
Total
|
||||||||||||||||||||||
Capital and
|
Deferred
|
during
the
|
stockholders'
|
|||||||||||||||||||||
Common
stock
|
subscription
on
|
stock-based
|
development
|
equity
|
||||||||||||||||||||
Number
|
Amount
|
shares
|
compensation
|
stage
|
(deficiency)
|
|||||||||||||||||||
Balance
as of December 31, 2006
|
24,201,812 | $ | 1 | $ | 24,427 | $ | - | $ | (26,244 | ) | $ | (1,816 | ) | |||||||||||
Stock-based
compensation related to options and shares granted to service
providers
|
544,095 | 1,446 | - | - | 1,446 | |||||||||||||||||||
Warrants
issued to convertible note holder
|
- | - | 109 | - | - | 109 | ||||||||||||||||||
Stock-based
compensation related to shares and options granted to directors and
employees
|
200,000 | * - | 1,232 | - | - | 1,232 | ||||||||||||||||||
Beneficial
conversion feature related to convertible loans
|
- | - | 407 | - | - | 407 | ||||||||||||||||||
Conversion
of convertible loans
|
725,881 | * - | 224 | - | - | 224 | ||||||||||||||||||
Exercise
of warrants
|
3,832,621 | * - | 214 | - | - | 214 | ||||||||||||||||||
Stock
issued for private placement at $0.1818 per unit, net of finder's
fee
|
11,500,000 | 1 | 1,999 | - | - | 2,000 | ||||||||||||||||||
Net
loss
|
- | - | - | - | (6,244 | ) | (6,244 | ) | ||||||||||||||||
Balance
as of December 31, 2007
|
41,004,409 | $ | 2 | $ | 30,058 | $ | - | $ | (32,488 | ) | $ | (2,428 | ) | |||||||||||
Stock-based
compensation related to options and stock granted to service
providers
|
90,000 | - | 33 | - | - | 33 | ||||||||||||||||||
Stock-based
compensation related to stock and options granted to directors and
employees
|
- | 731 | - | - | 731 | |||||||||||||||||||
Conversion
of convertible loans
|
3,644,610 | * - | 1,276 | - | - | 1,276 | ||||||||||||||||||
Exercise
of warrants
|
1,860,000 | * - | - | - | - | - | ||||||||||||||||||
Exercise
of options
|
17,399 | * - | 3 | - | - | 3 | ||||||||||||||||||
Stock
issued for private placement at $0.1818 per unit, net of finder's
fee
|
8,625,000 | 1 | 1,499 | - | - | 1,500 | ||||||||||||||||||
Subscription
of shares for private placement at $0.1818 per
unit
|
- | - | 281 | - | - | 281 | ||||||||||||||||||
Net
loss
|
- | - | - | - | (3,472 | ) | (3,472 | ) | ||||||||||||||||
Balance
as of December 31, 2008
|
55,241,418 | $ | 3 | $ | 33,881 | $ | - | $ | (35,960 | ) | $ | (2,076 | ) |
Common
stock
|
Additional
paid-in
|
Deferred
stock-based
|
Deficit
accumulated
during
the
development
|
Total
stockholders'
|
||||||||||||||||||||
Number
|
Amount
|
capital
|
compensation
|
stage
|
(deficiency)
|
|||||||||||||||||||
Balance
as of December 31, 2008
|
55,241,418 | $ | 3 | $ | 33,881 | $ | - | $ | (35,960 | ) | $ | (2,076 | ) | |||||||||||
Stock-based
compensation related to options and stock granted to service
providers
|
- | - | 9 | - | - | 9 | ||||||||||||||||||
Stock-based
compensation related to stock and options granted to directors and
employees
|
- | - | 109 | - | - | 109 | ||||||||||||||||||
Subscription
of shares for private placement at $0.1818 per
unit
|
- | - | 191 | - | - | 191 | ||||||||||||||||||
Net
loss
|
- | - | - | - | (514 | ) | (514 | ) | ||||||||||||||||
Balance
as of March 31, 2009
|
55,241,418 | $ | 3 | $ | 34,190 | $ | - | $ | (36,474 | ) | $ | (2,281 | ) |
Three
months ended
March
31,
|
Period
from
September
22,
2000
(inception
date)
through
March
31,
|
|||||||||||
2009
|
2008
|
2009
|
||||||||||
Cash
flows from operating activities:
|
||||||||||||
Net
loss
|
$ | (514 | ) | $ | (1,262 | ) | $ | (36,474 | ) | |||
Less
- loss for the period from discontinued operations
|
164 | |||||||||||
Adjustments
to reconcile net loss to net cash used in operating
activities:
|
||||||||||||
Depreciation
and amortization of deferred charges
|
39 | 33 | 557 | |||||||||
Severance
pay, net
|
(4 | ) | (6 | ) | 27 | |||||||
Accrued
interest on loans
|
4 | 41 | 434 | |||||||||
Amortization
of discount on short-term loans
|
- | 36 | 1,865 | |||||||||
Change
in fair value of options and warrants
|
- | - | (795 | ) | ||||||||
Expenses
related to shares and options granted to service providers
|
9 | 70 | 20,175 | |||||||||
Amortization
of deferred stock-based compensation related to options granted to
employees
|
109 | 199 | 4,997 | |||||||||
Decrease
(increase) in accounts receivable and prepaid expenses
|
(21 | ) | 70 | (42 | ) | |||||||
Increase
(decrease) in trade payables
|
20 | (26 | ) | 764 | ||||||||
Increase
in other accounts payable and accrued expenses
|
193 | 182 | 1,859 | |||||||||
Erosion
of restricted cash
|
3 | (3 | ) | (3 | ) | |||||||
Net
cash used in continuing operating activities
|
$ | (162 | ) | $ | (666 | ) | $ | (6,472 | ) | |||
Net
cash used in discontinued operating activities
|
- | - | (23 | ) | ||||||||
Total
net cash used in operating activities
|
$ | (162 | ) | $ | (666 | ) | $ | (6,495 | ) | |||
Cash flows from investing
activities:
|
||||||||||||
Purchase
of property and equipment
|
$ | $ | (157 | ) | $ | (1,080 | ) | |||||
Restricted
cash
|
- | - | (29 | ) | ||||||||
Investment
in lease deposit
|
5 | (7 | ) | (6 | ) | |||||||
Net
cash used in continuing investing activities
|
$ | 5 | $ | (164 | ) | $ | (1,115 | ) | ||||
Net
cash used in discontinued investing activities
|
- | - | (16 | ) | ||||||||
Total
net cash used in investing activities
|
$ | 5 | $ | (164 | ) | $ | (1,131 | ) | ||||
|
||||||||||||
Cash flows from financing
activities:
|
||||||||||||
Proceeds
from issuance of Common stock, net
|
$ | 191 | $ | 730 | $ | 6,059 | ||||||
Proceeds
from loans, notes and issuance of warrants, net
|
- | - | 2,061 | |||||||||
Credit
from bank
|
(34 | ) | 11 | 38 | ||||||||
Proceeds
from exercise of warrants and options
|
- | 3 | 28 | |||||||||
Repayment
of short-term loans
|
- | - | (601 | ) | ||||||||
Net
cash provided by continuing financing activities
|
$ | 157 | $ | 744 | $ | 7,585 | ||||||
Net
cash provided by discontinued financing activities
|
- | - | 43 | |||||||||
Total
net cash provided by financing activities
|
$ | 157 | $ | 744 | $ | 7,628 | ||||||
Increase
(decrease) in cash and cash equivalents
|
- | (86 | ) | 2 | ||||||||
Cash
and cash equivalents at the beginning of the period
|
2 | 86 | - | |||||||||
Cash
and cash equivalents at end of the period
|
$ | 2 | $ | - | $ | 2 |
NOTE
1
|
-
|
GENERAL
|
|
A.
|
On
July 8, 2004, the Company entered into a licensing agreement with Ramot of
Tel Aviv University Ltd. ("Ramot"), an Israeli corporation, to acquire
certain stem cell technology (see Note 3). Subsequent to this agreement,
the Company decided to focus on the development of novel cell therapies
for neurodegenerative diseases, particularly Parkinson's disease, based on
the acquired technology and research to be conducted and funded by the
Company.
|
Following
the licensing agreement dated July 8, 2004, the management of the Company
decided to abandon all old activities related to the sale of the digital
data recorder product. The discontinuation of this activity was accounted
for under the provision of Statement of Financial Accounting Standard
("SFAS") 144, "Accounting for the Impairment or Disposal of Long-Lived
Assets".
|
|
B.
|
On
November 22, 2004, the Company changed its name from Golden Hand Resources
Inc. to Brainstorm Cell Therapeutics Inc. to better reflect its new line
of business in the development of novel cell therapies for
neurodegenerative diseases. BCT owns all operational property and
equipment.
|
|
C.
|
On
October 25, 2004, the Company formed a wholly-owned subsidiary in Israel,
Brainstorm Cell Therapeutics Ltd.
("BCT").
|
|
D.
|
On
December 2006, the Company changed its state of incorporation from
Washington to Delaware.
|
|
E.
|
On
September 17, 2006, the Company's Board determined to change the Company's
fiscal year-end from March 31 to December
31.
|
|
F.
|
Since
its inception, the Company has devoted substantially most of its efforts
to research and development, recruiting management and technical staff,
acquiring assets and raising capital. In addition, the Company has not
generated revenues. Accordingly, the Company is considered to be in the
development stage, as defined in Statement of Financial Accounting
Standards No. 7, "Accounting and reporting by development Stage
Enterprises" ("SFAS No. 7").
|
|
GOING
CONCERN
|
As reflected
in the accompanying financial statements, the Company’s operations for the
three months ended on March 31, 2009, resulted in a net loss of $514 and
the Company’s balance sheet reflects a net stockholders’ deficiency of
$2,281, accumulated deficit of $36,474 and working capital deficiency of
$2,964. These conditions raise substantial doubt about the Company's
ability to continue to operate as a going concern. The Company’s ability
to continue operating as a “going concern” is dependent on several
factors, among them is its ability to raise sufficient additional working
capital. Management’s plans in this regard include, among others, raising
additional cash from current and potential stockholders and
lenders.
|
NOTE
1
|
-
|
GENERAL
(Cont.)
|
NOTE
3
|
-
|
UNAUDITED INTERIM
CONSOLIDATED FINANCIAL
STATEMENTS
|
|
A.
|
On
July 26, 2007, the Company entered into a Second Amended and Restated
Research and License Agreement with Ramot. On August 1, 2007, the Company
obtained a waiver and release from Ramot pursuant to which Ramot agreed to
an amended payment schedule regarding the Company's payment obligations
under the Amended Research and License Agreement, dated March 30, 2006,
and waived all claims against the Company resulting from the Company's
previous defaults and non-payment under the Original Agreement and the
Amended Research and License Agreement. The payments described in the
waiver and release covered all payment obligations that were past due and
not yet due pursuant to the Original Agreement. The waiver and release
amends and restates the original payment schedule under the Original
Agreement as follows:
|
Payment
date
|
Amount
|
|||
September
5, 2007
|
100 | |||
November
20, 2007
|
150 | |||
February
20, 2008
|
150 | |||
May
20, 2008
|
150 | |||
August
4, 2008
|
90 |
Payment
date
|
Amount
|
|||
August
4, 2008
|
60 | |||
November
20, 2008
|
150 | |||
February
20, 2009
|
170 |
|
B.
|
The
Company's total current obligation to Ramot as of March 31, 2009, is in
the amount of $867. The amount includes $570 for the extended research
period.
|
|
A.
|
On
July 8, 2004, the Company entered into two consulting agreements with
Prof. Eldad Melamed and Dr. Daniel Offen (together, the "Consultants"),
upon which the Consultants shall provide the Company scientific and
medical consulting services in consideration for a monthly payment of $6
each. In addition, the Company granted each of the Consultants, a fully
vested warrant to purchase 1,097,215 shares of Common Stock at an exercise
price of $0.01 per share. The warrants issued pursuant to the agreement
were issued to the Consultants effective as of November 4, 2004. Each of
the warrants is exercisable for a seven-year period beginning on November
4, 2005.
|
|
B.
|
As
of March 31, 2009, the Company has a total obligation of $262 for services
rendered by the Consultants.
|
|
A.
|
On
April 13, 2008, the Company entered into a new agreement with a lender
which the lender agreed to partially defer and partially convert to the
Company’s Common Stock the payment of $1,250 owed by the Company to the
lender based on the payment agreement between the two
parties.
|
Payment
date
|
Amount
|
|||
May
30, 2008
|
50 | |||
July
31, 2008
|
50 | |||
September
30, 2008
|
50 | |||
December
31, 2008
|
50 | |||
February
28, 2009
|
50 |
|
B.
|
In
addition, the Company issued 2,857,142 shares of common stock to the
lender in lieu of the repayment of $1,000 of the
Debt.
|
|
A.
|
The
rights of Common Stock are as
follows:
|
|
B.
|
Issuance
of shares, warrants and options:
|
|
1.
|
Private
placements:
|
|
a)
|
On
June 24, 2004, the Company issued to investors 8,510,000 shares of Common
Stock for total proceeds of $60 (net of $25 issuance
expenses).
|
|
b)
|
On
February 23, 2005, the Company completed a private placement for sale of
1,894,808 units for total proceeds of $1,418. Each unit consists of one
share of Common Stock and a three-year warrant to purchase one share of
Common Stock at $2.50 per share. This private placement was consummated in
three tranches which closed in October 2004, November 2004 and February
2005.
|
|
c)
|
On
May 12, 2005, the Company issued to an investor 186,875 shares of Common
Stock for total proceeds of $149 at a price of $0.8 per
share.
|
B.
|
Issuance
of shares, warrants and options:
(Cont.)
|
1.
|
Private
placements: (Cont.)
|
d)
|
On
July 27, 2005, the Company issued to investors 165,000 shares of Common
Stock for total proceeds of $99 at a price of $0.6 per
share.
|
e)
|
On
August 11, 2005, the Company signed a private placement agreement with
investors for the sale of up to 1,250,000 units at a price of $0.8 per
unit. Each unit consists of one share of Common Stock and one warrant to
purchase one share of Common Stock at $1.00 per share. The warrants are
exercisable for a period of three years from issuance. On September 30,
2005, the Company sold 312,500 units for total net proceeds of $225. On
December 7, 2005, the Company sold 187,500 units for total net proceeds of
$135.
|
f)
|
On
July 2, 2007, the Company entered into an investment agreement, pursuant
to which the Company agreed to sell up to 27,500,000 shares of Common
Stock, for an aggregate subscription price of up to $5 million and
warrants to purchase up to 30,250,000 shares of Common Stock. Separate
closings of the purchase and sale of the shares and the warrants shall
take place as follows:
|
Purchase
date
|
Purchase
price
|
Number
of
subscription
shares
|
Number
of
warrant
shares
|
|||||||||
August
30, 2007
|
$1,250
(includes $250
paid
as a convertible
loan
(Note 8i))
|
6,875,000 | 7,562,500 | |||||||||
November
15, 2007
|
$ | 750 | 4,125,000 | 4,537,500 | ||||||||
February
15, 2008
|
$ | 750 | 4,125,000 | 4,537,500 | ||||||||
May
15, 2008
|
$ | 750 | 4,125,000 | 4,537,500 | ||||||||
July
30, 2008
|
$ | 750 | 4,125,000 | 4,537,500 | ||||||||
November
15, 2008
|
$ | 750 | 4,125,000 | 4,537,500 |
B.
|
Issuance
of shares, warrants and options:
(Cont.)
|
1.
|
Private
placements: (Cont.)
|
|
f)
|
Cont.
|
2.
|
Share-based
compensation to employees and to
directors:
|
a)
|
Options
to employees and directors:
|
B.
|
Issuance
of shares, warrants and options:
(Cont.)
|
2.
|
Share-based
compensation to employees and to directors:
(Cont.)
|
a)
|
Options
to employees and directors:
(Cont.)
|
B.
|
Issuance
of shares, warrants and options:
(Cont.)
|
2.
|
Share-based
compensation to employees and to directors:
(Cont.)
|
a)
|
Options
to employees and directors:
(Cont.)
|
B.
|
Issuance
of shares, warrants and options:
(Cont.)
|
2.
|
Share-based
compensation to employees and to directors:
(Cont.)
|
a)
|
Options
to employees and directors:
(Cont.)
|
b)
|
Restricted
shares to directors:
|
3.
|
Shares
and warrants to service
providers:
|
B.
|
Issuance
of shares, warrants and options:
(Cont.)
|
3.
|
Shares
and warrants to service providers:
(Cont.)
|
a)
|
Warrants:
|
Issuance
date
|
Number
of
warrants
issued
|
Exercised
|
Forfeited
|
Outstanding
|
Exercise
Price
$
|
Warrants
exercisable
|
Exercisable
through
|
||||||||||||||||||
November
2004
|
12,800,845 | 3,141,925 | 40,000 | 9,618,920 | 0.01 | 9,618,920 |
November
2012
|
||||||||||||||||||
December
2004
|
1,800,000 | 1,800,000 | - | 0.00005 | — |
-
|
|||||||||||||||||||
February
2005
|
1,894,808 | 1,894,808 | - | 2.5 | - | ||||||||||||||||||||
May
2005
|
47,500 | 47,500 | 1.62 | 47,500 |
May
2010
|
||||||||||||||||||||
June
2005
|
30,000 | 30,000 | 0.75 | 30,000 |
June
2010
|
||||||||||||||||||||
August
2005
|
70,000 | 70,000 | - | 0.15 | - |
-
|
|||||||||||||||||||
September
2005
|
3,000 | 3,000 | - | 0.15 | - |
-
|
|||||||||||||||||||
September
2005
|
36,000 | 36,000 | 0.75 | 36,000 |
September
2010
|
||||||||||||||||||||
September-December
2005
|
500,000 | 500,000 | - | 1 | - |
-
|
|||||||||||||||||||
December
2005
|
20,000 | 20,000 | - | 0.15 | - |
-
|
|||||||||||||||||||
December
2005
|
457,163 | 457,163 | 0.15 | 457,163 |
July
2010
|
||||||||||||||||||||
February
2006
|
230,000 | 230,000 | 0.65 | 230,000 |
February
2008
|
||||||||||||||||||||
February
2006
|
40,000 | 40,000 | 1.5 | 40,000 |
February
2011
|
||||||||||||||||||||
February
2006
|
8,000 | 8,000 | 0.15 | 8,000 |
February
2011
|
||||||||||||||||||||
February
2006
|
189,000 | 97,696 | 91,304 | - | 0. 5 | - |
-
|
||||||||||||||||||
May
2006
|
50,000 | 50,000 | 0.0005 | 50,000 |
May
2016
|
||||||||||||||||||||
May
-December 2006
|
48,000 | 48,000 | 0.35 | 48,000 |
May - December 2011
|
||||||||||||||||||||
May
-December 2006
|
48,000 | 48,000 | 0.75 | 48,000 |
May - December 2011
|
||||||||||||||||||||
May
2006
|
200,000 | 200,000 | 1 | 200,000 |
May
2011
|
||||||||||||||||||||
June
2006
|
24,000 | 24,000 | 0.15 | 24,000 |
June
2011
|
||||||||||||||||||||
May
2006
|
19,355 | 19,355 | 0.15 | 19,355 |
May
2011
|
||||||||||||||||||||
October
2006
|
630,000 | 630,000 | - | 0.3 | - |
-
|
|||||||||||||||||||
December
2006
|
200,000 | 200,000 | - | 0.45 | - |
-
|
|||||||||||||||||||
March
2007
|
200,000 | 200,000 | 0.47 | 200,000 |
March
2012
|
||||||||||||||||||||
March
2007
|
500,000 | 500,000 | 0.47 | 333,333 |
March
2017
|
||||||||||||||||||||
March
2007
|
50,000 | 50,000 | 0.15 | 50,000 |
March
2010
|
||||||||||||||||||||
March
2007
|
15,000 | 15,000 | 0.15 | 15,000 |
February
2012
|
||||||||||||||||||||
February
2007
|
50,000 | 50,000 | - | 0.45 | - |
-
|
|||||||||||||||||||
March
2007
|
225,000 | 225,000 | - | 0.45 | - |
-
|
|||||||||||||||||||
March
2007
|
50,000 | 50,000 | 0.45 | 50,000 |
March
2010
|
||||||||||||||||||||
April
2007
|
33,300 | 33,300 | 0.45 | 33,300 |
April
2009
|
||||||||||||||||||||
May
2007
|
250,000 | 250,000 | - | 0.45 | - |
-
|
|||||||||||||||||||
July
2007
|
500,000 | 500,000 | 0.39 | 277,778 |
July
2017
|
||||||||||||||||||||
September
2007
|
500,000 | 500,000 | 0.15 | 500,000 |
August
2017
|
||||||||||||||||||||
August
2007
|
7,562,500 | 7,562,500 | 0.2 | 7,562,500 |
November
2011
|
||||||||||||||||||||
July
2007
|
30,000 | 30,000 | 0.45 | 30,000 |
July
2009
|
||||||||||||||||||||
July
2007
|
100,000 | 100,000 | 0.45 | 100,000 |
July
2010
|
||||||||||||||||||||
October
2007
|
200,000 | 200,000 | 0.15 | 200,000 |
August - October 2017
|
||||||||||||||||||||
November
2007
|
2,520,833 | 2,520,833 | 0.20 | 2,520,833 |
November
2011
|
||||||||||||||||||||
November
2007
|
2,016,667 | 2,016,667 | 0.29 | 2,016,667 |
November
2011
|
||||||||||||||||||||
April
2008
|
4,537,500 | 4,537,500 | 0.29 | 4,537,500 |
November
2011
|
||||||||||||||||||||
August
2008
|
3,529,166 | 3,529,166 | 0.29 | 3,529,166 |
November
2011
|
||||||||||||||||||||
August
2008
|
1,083,333 | 1,083,333 | 0.36 | 1,008,333 |
November
2011
|
||||||||||||||||||||
November
2008
|
100,000 | 100,000 | 0.15 | 100,000 |
September
2018
|
||||||||||||||||||||
43,323,970 | 5,692,621 | 3,321,112 | 34,310,237 | 33,921,349 |
B.
|
Issuance
of shares, warrants and options:
(Cont.)
|
3.
|
Shares
and warrants to service providers:
(Cont.)
|
a)
|
Warrants:
|
b)
|
Shares:
|
B.
|
Issuance
of shares, warrants and options:
(Cont.)
|
3.
|
Shares
and warrants to service providers:
(Cont.)
|
b)
|
Shares:
|
B.
|
Issuance
of shares, warrants and options:
(Cont.)
|
3.
|
Shares
and warrants to service providers:
(Cont.)
|
b)
|
Shares:
|
B.
|
Issuance
of shares, warrants and options:
(Cont.)
|
3.
|
Shares
and warrants to service providers:
(Cont.)
|
b)
|
Shares:
|
Three
months ended
March
31,
|
Period
from
September
22,
2000
(inception
date)
through
March
31,
|
|||||||||||
2009
|
2008
|
2009
|
||||||||||
Research
and development
|
30 | 45 | 16,655 | |||||||||
General
and administrative
|
88 | 205 | 7,671 | |||||||||
Financial
expenses, net
|
- | - | 56 | |||||||||
Total
stock-based compensation expense
|
118 | 250 | 24,382 |
A.
|
On
April 13, 2009 , the Company's Board passed the following
resolutions:
|
1.
|
Issuance
of 250,000 restricted shares
to a Company advisor. The shares are for $25
unpaid debt to the advisor.
|
2.
|
Grant
option to purchase 200,000 shares of Common Stock at an exercise price of
$0.1 per share to the Company's legal advisor for legal
services. The option vests and become exercisable on the first
anniversary of the grant
date.
|
3.
|
Election
Abraham (Rami) Efrati, the company's CEO, to the Board of
Directors.
|
1.
|
On
April 2, 2009 the Company and a lender agreed of Issuance of 2,500,000
restricted shares of common stock to the lender. The shares are for the
$200 unpaid loan to the lender (see note
6b).
|
2.
|
On
April 5, 2009 the company and it's chief technology advisor agreed of
Issuance of 1,800,000 restricted shares of common stock to the chief
technology advisor. The shares are for the $180 unpaid debt to the
advisor.
|
·
|
Developing the cell
differentiation process according to Food and Drug Administration (“FDA”)
and the European agency for evaluation of medical product (“EMEA”)
guidelines;
|
·
|
Demonstrating safety and efficacy
first in animals and then in human patients;
and
|
·
|
Setting up centralized facilities
to provide NurOwn™ therapeutic products and services for transplantation
in patients.
|
·
|
our ability to obtain funding
from third parties, including any future collaborative
partners;
|
·
|
the scope, rate of progress and
cost of our clinical trials and other research and development
programs;
|
·
|
the time and costs required to
gain regulatory approvals;
|
·
|
the terms and timing of any
collaborative, licensing and other arrangements that we may
establish;
|
·
|
the costs of filing, prosecuting,
defending and enforcing patents, patent applications, patent claims,
trademarks and other intellectual property
rights;
|
·
|
the effect of competition and
market developments; and
|
·
|
future pre-clinical and clinical
trial results.
|
·
|
The Company did not maintain
effective controls over certain aspects of the financial reporting process
because we lacked a sufficient complement of personnel with a level of
accounting expertise and an adequate supervisory review structure that is
commensurate with the Company’s financial reporting requirements.
Specifically, our Chief Financial Officer handles all accounting issues of
the Company alone as the Company recently terminated the Company’s
accountant as part of the downsizing of the Company’s
staff.
|
BRAINSTORM
CELL THERAPEUTICS INC.
|
||
May
14, 2009
|
By:
|
/s/
Rami Efrati
|
Name:
Rami Efrati
Title:
Chief Executive Officer (Principal
Executive Officer)
|
May
14, 2009
|
By:
|
/s/ David
Stolick
|
Name:
David Stolick
Title:
Chief Financial Officer (Principal Financial
and
Accounting
Officer)
|
Exhibit
Number
|
Description
|
|
31.1
|
Certification
of the Principal Executive Officer pursuant to Section 302 of the
Sarbanes-Oxley Act of 2002.
|
|
31.2
|
Certification
of the Principal Financial Officer pursuant to Section 302 of the
Sarbanes-Oxley Act of 2002.
|
|
32.1
|
Certification
of the Principal Executive Officer pursuant to 18 U.S.C. Section 1350, as
adopted pursuant to Section 906 of the Sarbanes-Oxley Act of
2002.
|
|
32.2
|
Certification
of the Principal Financial Officer pursuant to 18 U.S.C. Section 1350, as
adopted pursuant to Section 906 of the Sarbanes-Oxley Act of
2002.
|